Clinical Trials Logo

Non-Small Cell Lung Cancer clinical trials

View clinical trials related to Non-Small Cell Lung Cancer.

Filter by:

NCT ID: NCT06312137 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without MK- 2870 in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Start date: April 23, 2024
Phase: Phase 3
Study type: Interventional

This study will assess if adding MK-2870 with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is MK-2870 plus pembrolizumab is superior to pembrolizumab monotherapy with respect to disease free survival (DFS) as assessed by blinded independent central review (BICR).

NCT ID: NCT06311981 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients

Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

To observe the effect and toxicity of carbon ion radiotherapy on local advanced non-small cell lung cancer over 75 years old patients. Systemic therapy could be targeted therapy, chemotherapy or immunotherapy.

NCT ID: NCT06305962 Recruiting - Clinical trials for Non Small Cell Lung Cancer

177Lu-anti-PD-L1 sdAb in Metastatic Non-small Cell Lung Cancer

Start date: March 2024
Phase: Early Phase 1
Study type: Interventional

This is a first-in-human, open-label study consisting of a Screening Period, an Imaging Period, and a Treatment Period in eligible non-small lung cancer patients who are positive for the biomarker PDL-1. The Screening period lasts up to 4 weeks. The Phase 0 (Imaging Period) is used to determine if patient's tumor(s) are still positive for the biomarker, as well as radiation dosimetry with low dose 177Lu-RAD204im (for a period of up to 2 weeks following the first injection of 177Lu-RAD204im), to assess the safety of the drug. Following the 2 week safety assessment, the subject is eligible to enter Phase I (Treatment Period) with gradual dose increases of 177Lu-RAD204tr. The Treatment Period lasts up to 3 cycles every 6 weeks, with additional extension to a maximum study dose interval of 12 weeks to be approved on a case-by-case basis in discussion with study Sponsor. During the Treatment Period, subjects will be assessed for both safety and treatment response using conventional images and clinical laboratory tests.

NCT ID: NCT06305715 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer

Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)

Start date: April 15, 2024
Phase: Phase 2
Study type: Interventional

This prospective, two-part, single-arm, phase II trial is designed to evaluate whether the use of definitive radiation to the primary lung lesion prolongs progression-free survival (PFS) in treatment-naïve, metastatic, driver-mutated non-small cell lung cancers (NSCLC) patients who are subsequently placed on a tyrosine kinase inhibitor (TKI).

NCT ID: NCT06304805 Completed - Clinical trials for Non Small Cell Lung Cancer

TGRX-326 Food Effect Pharmacokinetic Study

Start date: December 13, 2023
Phase: Phase 1
Study type: Interventional

A study evaluating the effects of food intake on the pharmacokinetic (PK) profiles of TGRX-326 and the effect of different drug specifications on human bioavailability for TGRX-326, a drug indicated for non-small cell lung cancer treatment

NCT ID: NCT06303505 Not yet recruiting - Ovarian Cancer Clinical Trials

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

NAPISTAR1-01
Start date: May 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this multicentric, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best dose of TUB-040 in patients with ovarian cancer and Non Small Cell Lung Cancer. TUB-040 is an antibody-drug-conjugate which delivers a topoisomerase I inhibitor to tumor cells which overexpress the target NaPi2b. The study consists of two parts: In dose escalation, ovarian cancer patients and lung cancer patients receive increasing doses of TUB-040 until the maximal tolerated dose is found. In dose optimization, at least two doses are compared with each other to determine which dose is optimal for patients. TUB-040 is given IV every 3 weeks until the disease progresses or the patient has to stop due to side effects.

NCT ID: NCT06300424 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC

NEOVADE
Start date: April 2024
Phase: Phase 2
Study type: Interventional

Phase II, single-arm, open-label study that assess clinical feasibility and safety of neoadjuvant almonertinib followed by 3 cycles neoadjuvant adebrelimab plus chemotherapy in EGFR-mutant stage IIA-IIIB NSCLC followed by surgery, adjuvant treatment was upon investigators' decisions.

NCT ID: NCT06300177 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer

D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

Start date: April 2024
Phase: Phase 3
Study type: Interventional

The purpose of this project is to evaluate progression-free survival (PFS) of D-1553 Tablet versus Docetaxel Injection in subjects with prior standard therapy failure kirsten rat sarcoma viral oncogene (KRAS) G12C mutation positive locally advanced or metastatic non small cell lung cancer (NSCLC), progression-free survival (PFS) as assessed by the Independent Review Committee (IRC) based on RECIST 1.1 was used as the primary endpoint.

NCT ID: NCT06299371 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer

Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations

Start date: April 15, 2024
Phase: Phase 2
Study type: Interventional

This is a prospective, single-arm study to investigate the efficacy and safety of Adebrelimab in combination with paclitaxel for injection (albumin bound) and platinum chemotherapy as neoadjuvant therapy in resectable non-small cell lung cancer harboring driver gene mutations

NCT ID: NCT06297811 Not yet recruiting - Breast Cancer Clinical Trials

Myeloprotection With Trilaciclib in Pan-cancer Population

Start date: March 1, 2024
Phase: Phase 2
Study type: Interventional

The goal of this open-label randomized controlled study is to assess the myeloprotective effect of trilaciclib in pan-cancer population. The main questions it aims to answer are: - effect and safety of trilaciclib on myeloprotection in cancer patients receiving paclitaxel plus carboplatin chemotherapy - does trilaciclib 's myeloprotective efficacy in patients receiving the same chemotherapy regimen correlate with tumor type Participants will be randomized 2:1 to the treatment arm of trilaciclib in combination with a paclitaxel and carboplatin-based regimen and the control arm of a paclitaxel and carboplatin-based regimen for at least 6 cycles or until disease progression or intolerable toxicity. Patients in both groups could extend the chemotherapy cycle at the investigator 's discretion depending on the tumor type and in combination with anti-angiogenic/PD-X/anti-HER2 therapy.